What a week out of Japan for investors! Japan's Nikkei (NIKKEIINDICES: ^NI225 ) stock index exploded on one of its best weekly runs in recent history, roaring higher by 7.6%. The Nikkei's been one of the best indexes across the world this year, and there's no slowing it down right now as Japan pushes forward in its stimulus moves and fight against decades of stagnation.
But can the Nikkei keep its run going through the end of the year? Japanese stocks have made many investors wealthy, but analysts and economists are concerned after Japan's economy hit a snag in its most recent quarter. Let's catch up on the latest.
Is Japan's growth slowing?
Japan's GDP growth slowed down to just 0.5% in the third quarter, recording an annualized growth rate of 1.9%. That's far less than the annualized rate of 3.8% seen in the prior quarter, although as Tokyo noted, it's still far better than the contraction the country was experiencing in 2012. There's no doubt that Prime Minister Shinzo Abe's economic expansion have jump-started an economy stuck in a rut until this year.
5 Best Consumer Service Stocks To Watch For 2015: TransAlta Corporation (TAC)
TransAlta Corporation operates as a non-regulated electricity generation and energy marketing company. The company engages in the production and sale of electric energy through its diversified portfolio of facilities fuelled by coal, natural gas, hydroelectric, wind, geothermal, and biomass resources in Canada, the United States, and Australia. It has an aggregate net ownership interest of approximately 8,025 megawatts of generating capacity in operation. The company was founded in 1911 and is based in Calgary, Canada.
Advisors' Opinion:- [By Nitish]
Google Inc. reported consolidated revenues of $15.96 billion for the quarter ended June 30, 2014, an increase of 22% compared to the second quarter of 2013. The company reports advertising revenues consistent with GAAP on a gross basis without deducting traffic acquisition costs (TAC). In the second quarter of 2014, TAC totaled $3.29 billion, or 23% of advertising revenues.
5 Best Consumer Service Stocks To Watch For 2015: MEDL Mobile Holdings Inc (MEDL)
MEDL Mobile Holdings, Inc. incorporated on May 22, 2008 is a developer, incubator, marketer and aggregator of mobile application software (Apps). The Company is engaged in the monetization of mobile application software through four revenue generating platforms: development of customized Apps for third parties to monetize their particular intellectual property, persona or brand, incubation of Apps in partnership with third parties and from a library of more than 75,000 original Apps concept submissions, sale of advertising and sponsorship opportunities directly to brands via mobile advertising networks and acquisition of Apps from other developers and use of a application programming interface ( API).
The Company develops Apps for customers that vary in size from small start-ups to large multinational corporations, in a range of industries including retailing, fast food, air travel, medical devices, higher education and fashion. As of December 31, 2011, revenues its custom development accounted for approximately 93% of its total revenues. The Company prepares packages for sale in the Apple App Store and the Google Android Marketplace. This package includes app store copy, sample screen shots.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Digital Caddies Inc (OTCMKTS: CADY), MEDL Mobile Holdings Inc (OTCMKTS: MEDL) and Yappn Corp (OTCMKTS: YPPN) offer different ways to potentially profit from Internet or mobile technology. However, all three small cap stocks have also been the subject of paid promotions or investor relations types of activities. So will investors actually profit from the efforts of these small caps to profit from the Internet or mobile technology? Here is a quick reality check:
Top 10 Casino Companies To Watch In Right Now: Anworth Mortgage Asset Corporation (ANH)
Anworth Mortgage Asset Corporation operates as a real estate investment trust (REIT) in the United States. It invests primarily in the United States agency mortgage-backed securities (agency MBS) guaranteed by the United States government, including pass-through certificates, collateralized mortgage obligations (CMOs), and other types of MBS, such as mortgage derivative securities and mortgage warehouse participations, as well as in other mortgage related assets. The company's agency MBS portfolio includes adjustable-rate agency MBS, hybrid adjustable-rate agency MBS, fixed-rate Agency MBS, and agency floating-rate CMOs. It also invests in non-agency mortgage-backed securities comprising floating-rate CMOs. The company qualifies as a REIT for federal income tax purposes. As a REIT it would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Anworth Mortgage Asset Corporation was founded in 1997 and is b ased in Santa Monica, California.
Advisors' Opinion:- [By alicet236]
Anworth Mortgage Asset Corporation (ANH) Reached the Five-Year Low of $4.47
The prices of Anworth Mortgage Asset Corporation (ANH) shares have declined to close to the five-year low of $4.47, which is 49.3% off the five-year high of $8.340. Anworth Mortgage Asset Corporation is owned by one Guru we are tracking. Among them, one added to his positions during the past quarter. Two reduced their positions. Anworth Mortgage Asset Corporation has a market cap of $639.1 million; its shares were traded at around $4.47 with a P/E ratio of 7.10 and P/S ratio of 5.96. The dividend yield of Anworth Mortgage Asset Corporation stocks is 12.80%.
- [By Rich Duprey]
Externally managed REIT�Anworth Mortgage Asset (NYSE: ANH ) announced yesterday its second-quarter dividend of $0.15 per share, the same rate it's paid for the past three quarters after cutting the payout 17% from $0.18 per share. The quarter before that, the REIT had cut the dividend 14% more.
5 Best Consumer Service Stocks To Watch For 2015: Sigma-Aldrich Corp (SIAL)
Sigma-Aldrich Corporation, incorporated in May 12, 1975, is a life science and high technology company. The Company develops, manufactures, purchases and distributes the range of chemicals, biochemicals and equipment available globally and also provides global biopharmaceutical testing services. These chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. As of December 31, 2012, the Company offered approximately 45,000 equipment products. On January 31, 2012, the Company completed its acquisition of all of interest of BioReliance, a provider of global biopharmaceutical testing services. On April 2, 2012, the Company acquired Research Organics, a supplier of purity biochemicals.
The Company provides products and services that focus on research customers that use smaller quantities of its products in basic life science and high-technology research and development (R&D); manufacturing customers that use its products in quantities in lab-stage development and manufacturing; life science customers who use its biopharmaceutical testing services to facilitate the development, manufacturing and commercialization of biological drugs, and industrial and diagnostic companies that use its products in range of forms of assays and testing, as well as in clinical diagnostics. The Company has a customer base of commercial laboratories, pharmaceutical companies, industrial companies, universities, diagnostics companies, biotechnology companies, electronics companies, hospitals, governmental institutions and non-profit organizations located in the United States and globally.
Advisors' Opinion:- [By Monica Gerson]
Sigma-Aldrich (NASDAQ: SIAL) is expected to report its Q3 earnings at $0.99 per share on revenue of $661.29 million.
CR Bard (NYSE: BCR) is projected to post its Q3 earnings at $1.40 per share on revenue of $739.62 million.
- [By Nicole Seghetti]
2. Sigma-Aldrich (NASDAQ: SIAL )
Maker of test tubes and beakers, Sigma-Aldrich has increased its dividend every year since 1976. Even though the company pays a relatively scrawny 1.1% dividend yield, its 21% payout ratio signals the company has ample opportunity to up its dividend for many years to come. - [By ovenerio]
Over the past days hedge funds have been filing their form 13-F, which is a quarterly report of equity holdings by filed institutional investment managers with at least $100 million in equity assets under management, as required by the United States Securities and Exchange Commission (SEC). In this article, let麓s concentrate in one particular hedge fund and try to see the principal holdings in its portfolio. I will look into America First Investment Advisor.Recently the fund reported its equity portfolio, as at the end of June. The total value of the portfolio amounted to $222.9 million, up from $203.2 million disclosed at the end of the previous quarter. Consequently, the fund's total return was 9.7% in the last quarter. The filing revealed that at the end of June, the fund added 14 new positions to its equity portfolio, and sold out of 24 other companies. The top ten portfolio holdings as of the end of the quarter represented 41.8%. The largest changes from previous 13-F麓s fillings are in the tech and energy sectors.In this article, we have selected three companies, in which the fund holds the largest stakes, in terms of market value.The first on the list is The Clorox Company (CLX), in which the fund disclosed a $10.53 million stake with over 115,150 shares. The company is a diversified producer of household cleaning, grocery and specialty food products is also a leading producer of natural personal care products.Long-Term VisionIn October 2013, Clorox introduced its 2020 Strategy. The 2020 Strategy focuses on delivering long-term, profitable growth through the year 2020. The key elements of its strategy to grow sales and earnings over the long term are: category, channel and geographic expansion, increased brand investment, and cost reductions.The company's long-term financial goals include:Growing net sales 3-5 percent annuallyExpanding EBIT margin 25-50 basis points annuallyGenerating free cash flow of 10% to 12% of sales annuallyIt has improved earnings
- [By Maxx Chatsko]
Any company that creates products and relies on other companies to use and distribute them will inevitably forge strong relationships with its customers. It's an important thing to look into when investing, yet easy to overlook. Investors should know whether customers are reliable, which are leaned on the most, and if the company they own is too dependent on any customer (or a select few). Bioprocessing product company Repligen (NASDAQ: RGEN ) may make consumables that are the lifeline of the biotech industry, but its customer relationships are absolutely critical for smooth operations. Let's look at how the company interacts with the Life Sciences division of General Electric (NYSE: GE ) , EMD Millipore from Merck (NYSE: MRK ) , and Sigma-Aldrich (NASDAQ: SIAL ) -- the three most important customers.
5 Best Consumer Service Stocks To Watch For 2015: Achillion Pharmaceuticals Inc.(ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Advisors' Opinion:- [By Keith Speights]
Liver quivers
Achillion Pharmaceuticals (NASDAQ: ACHN ) ranks as the top drop of the week. Shares plunged 24% on news that the Food and Drug Administration placed a clinical hold on experimental hepatitis C drug�sovaprevir. - [By David Williamson]
In this video, David Williamson describes how Achillion Pharmaceuticals (NASDAQ: ACHN ) may challenge Gilead's (NASDAQ: GILD ) dominance in the Hepatitis C drug market. Achillion is concluding phase 2 clinical trials of its oral interferon medication, and so far, things are looking good. If successful in phase 3 trials, Achillion could directly challenge Gilead's interferon medication. For investors, the success of Achillion's drug is attractive, but the potential for Achillion to be a takeover target is even more enticing. The company has a market cap of around $575 million and could easily be bought out by the likes of Bristol-Myers Squibb.
- [By Keith Speights]
2. Achillion Pharmaceuticals (NASDAQ: ACHN )
Achillion recently experienced a delay in the game that it had hoped to play. The FDA placed a clinical hold on hepatitis C drug sovaprevir after patients in a phase 1 drug-drug interaction study with the drug combined with ritonavir-boosted atazanavir were found to have elevated liver enzyme levels. Shares dropped 25% in one day as a result. - [By Sean Williams]
In terms of clinical updates, hepatitis-C-focused biotech Achillion Pharmaceuticals (NASDAQ: ACHN ) announced updated midstage results for its lead compound, ACH-3102, on Tuesday. In trials of genotype-1b treatment naive patients, ACH-3102 plus a ribavirin delivered a 75% success rate in end-of-treatment virologic response. The problem with these results is that not only is Achillion far behind its all-oral peers in terms of development, but its 75% success rate trailed that of Gilead Sciences' Sofosbuvir, which delivered 100% success rates in some of its late-stage trials featuring genotype-1 patients.
No comments:
Post a Comment